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Annexin A5 reduces infarct size 
and improves cardiac function after 
myocardial ischemia-reperfusion 
injury by suppression of the cardiac 
inflammatory response
Rob C. M. de Jong1,2, Niek J. Pluijmert3, Margreet R. de Vries  1,2, Knut Pettersson4,  
Douwe E. Atsma3, J. Wouter Jukema1,3 & Paul H. A. Quax  1,2
Annexin A5 (AnxA5) is known to have anti-inflammatory and anti-apoptotic properties. Inflammation 
and apoptosis are key processes in post-ischemic cardiac remodeling. In this study, we investigated 
the effect of AnxA5 on left ventricular (LV) function and remodeling three weeks after myocardial 
ischemia-reperfusion (MI-R) injury in hypercholesterolemic ApoE*3-Leiden mice. Using a mouse model 
for MI-R injury, we demonstrate AnxA5 treatment resulted in a 27% reduction of contrast-enhanced 
MRI assessed infarct size (IS). End-diastolic and end-systolic volumes were decreased by 22% and 
38%, respectively. LV ejection fraction was increased by 29% in the AnxA5 group compared to vehicle. 
Following AnxA5 treatment LV fibrous content after three weeks was reduced by 42%, which was 
accompanied by an increase in LV wall thickness of the infarcted area by 17%. Two days and three weeks 
after MI-R injury the number of cardiac macrophages was significantly reduced in both the infarct 
area and border zones following AnxA5 treatment compared to vehicle treatment. Finally, we found 
that AnxA5 stimulation leads to a reduction of IL-6 production in bone-marrow derived macrophages 
in vitro. AnxA5 treatment attenuates the post-ischemic inflammatory response and ameliorates LV 
remodeling which improves cardiac function three weeks after MI-R injury in hypercholesterolemic 
ApoE*3-Leiden mice.
Acute myocardial infarction (MI) initiates a massive inflammatory response1,2 and cell death3. To limit myocar-
dial damage due to these processes and salvage ischemic myocardium, primary percutaneous coronary interven-
tion is the preferred clinical therapy to achieve reperfusion4. However, post-ischemic reperfusion itself causes 
reperfusion injury with the formation of reactive oxygen species which cause direct cell death and stimulation 
of signal transduction to generate inflammatory cytokines5. Furthermore, it has been shown that reperfusion 
induces and in particular aggravates apoptosis6,7. Through binding and ingestion of dying cells, myeloid cells can 
markedly influence immune responses by enhancing or suppressing inflammation indicating close interaction 
between cell death and inflammation8. In line with this affecting apoptosis and inflammation to mitigate cellular 
damage might result in new clinical therapies.
Myocardial ischemia-reperfusion (MI-R) induced apoptosis results in different (intra)cellular changes includ-
ing loss of the asymmetric distribution of plasma membrane phospholipids. Normally, the choline-containing 
lipid phosphatidylcholine is present on both the outer and inner membrane leaflet while aminophospholipids, like 
phosphatidylserine (PS), are concentrated on the inner membrane leaflet of viable cells. During early apoptosis 
and inflammatory cell activation, PS is externalized to the outer cell surface as a result of the activated proteolytic 
1Department of Surgery, Leiden University Medical Center, Albinusdreef 2, P.O. Box 9600, 2300 RC, Leiden, The 
Netherlands. 2Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, 
Albinusdreef 2, P.O. Box 9600, 2300 RC, Leiden, The Netherlands. 3Department of Cardiology, Leiden University 
Medical Center, Albinusdreef 2, P.O. Box 9600, 2300 RC, Leiden, The Netherlands. 4Athera Biotechnologies, Mölndal, 
Sweden. Rob C. M. de Jong and Niek J. Pluijmert contributed equally to this work. Correspondence and requests for 
materials should be addressed to P.H.A.Q. (email: P.H.A.Quax@lumc.nl)
Received: 2 May 2017
Accepted: 11 April 2018
Published: xx xx xxxx
OPEN
www.nature.com/scientificreports/
2SCientifiC RepoRts |  (2018) 8:6753  | DOI:10.1038/s41598-018-25143-y
enzyme caspase-3, where it functions as an “eat me” signal to ensure early recognition and phagocytosis9,10. 
Annexins are a family of phospholipid-binding proteins and in particular annexin A5 (AnxA5) binds reversibly, 
specifically and with high affinity to PS-expressing cells11. In addition to the first discovered anti-thrombotic 
effects of AnxA512,13, it is also known to have possible diagnostic properties in visualizing cell death14 including 
assessment of atherosclerotic plaque vulnerability15.
MI is reported to cause increased endogenous AnxA5 plasma levels16 and uptake in the infarct area17 in 
patients. After an ischemic event, cardiomyocytes were found to express PS on their cell surface for at least 6 hours. 
Administration of exogenous AnxA5 resulted in cytoplasmic internalization and restored sarcolemmal PS asym-
metry with no externalized PS remaining, thereby possibly reversing the apoptotic process18. Furthermore, a 
reduced post-interventional inflammatory response was observed following AnxA5 treatment resulting in a 
potential therapeutic effect against post-interventional intimal hyperplasia19 and accelerated atherosclerosis20.
Taken together, the anti-apoptotic and anti-inflammatory effects of AnxA5, can provide a possible role of 
human recombinant AnxA5 as a therapeutic agent to decrease post-ischemic left ventricular (LV) remodeling and 
improve cardiac function. A previous study showed beneficial effects of Diannexin, a dimer of AnxA5, treatment in 
rabbits on post-ischemic blood flow following ischemia and reperfusion21. In the current study we demonstrate the 
beneficial effects of AnxA5 treatment on infarct size (IS) and post-infarctional cardiac remodeling in a clinically 
more relevant setting, namely by starting the treatment post-reperfusion and using a follow-up up to three weeks. 
Cardiac function and IS were assessed three weeks post reperfusion. Moreover, the experiments are performed 
under hypercholesterolemic conditions by using ApoE*3-Leiden mice on a Western-type diet. Furthermore, we 
investigate the effect of AnxA5 treatment on the post ischemic-reperfused inflammatory response.
Results
Annexin A5 accumulates in the infarct area. First, AnxA5 accumulation in the infarct area follow-
ing AnxA5 treatment was evaluated using immunohistochemistry. Two days post MI-R AnxA5 staining, using 
a specific AnxA5 antibody, was clearly more intense in the infarct area of AnxA5 treated when compared to 
vehicle treated mice (Fig. 1), suggesting AnxA5 accumulation in the infarct area. Furthermore, as can be appre-
ciated from the images of sham operated mice, AnxA5 protein is present in the healthy myocardium. However, 
compared the infarcted myocardium, healthy myocardium shows AnxA5 staining which is evenly distributed 
throughout the tissue. Moreover, the exogenously added AnxA5 accumulates especially in the infarcted area with 
a spot-wise pattern. Total plasma cholesterol concentration, triglyceride levels and body weight were not affected 
by AnxA5 treatment (Supplementary Table S1).
Annexin A5 reduces contrast-enhanced MRI assessed LV infarct size. Infarct size as assessed by 
contrast-enhanced MRI was significantly reduced after three weeks in AnxA5 treated mice compared to the 
vehicle group (13.4 ± 1.8% vs. 18.3 ± 1.1%, P = 0.022; Fig. 2A), while initial IS, two days after MI-R, was compa-
rable in both groups (27.0 ± 2.3% vs. 30.6 ± 2.1%, P = 0.249; Fig. 2A). Interestingly, IS was significantly smaller 
(Supplementary Fig. S1A) three weeks post-reperfusion compared to two days post-reperfusion indicating infarct 
healing and resorption of acute infarct edema. This observation was confirmed by the absolute numbers of IS 
and viable myocardium. IS was decreased in both the vehicle and AnxA5 group after three weeks when com-
pared to two days (Supplementary Fig. S1B), while viable myocardium was unchanged in time (Supplementary 
Fig. S1C). Reduced IS does not affect heart weight, since heart weight was comparable in all three groups (AnxA5: 
145 ± 5 mg, vehicle: 140 ± 7 mg, and sham 144 ± 8 mg; Supplementary Table S1).
Figure 1. Annexin A5 staining. Representative images of cross-sections from the whole heart (left) or the 
infarct area (right) two days after MI-R stained for human annexin A5 using a specific AnxA5 antibody, while 
counterstaining was performed using haematoxilin. AnxA5 treated mice showed a more intense staining 
compared to vehicle and sham mice. Left panel scale bar: 500 μm, right panel scale bar: 20 μm.
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Annexin A5 improves LV function. MRI analyses showed that the reduced scar expansion after MI-R due to 
AnxA5 treatment was accompanied by a limitation of LV dilation and preserved LV function after three weeks. No 
differences were observed at day two (EDV: 31.0 ± 2.0 μl vs. 34.4 ± 2.3 μl, P = 1.000; Fig. 3A, and ESV: 14.2 ± 1.5 μl 
vs. 19.4 ± 2.0 μl, P = 0.153; Fig. 3B). However, after three weeks EDV was significantly smaller in the AnxA5 group 
as compared with vehicle (34.5 ± 2.2 μl vs. 44.4 ± 2.4 μl, P = 0.004; Fig. 3A). Furthermore, ESV was significantly 
smaller in the AnxA5 group as compared with vehicle (16.5 ± 1.4 μl vs. 26.6 ± 2.2 μl, P < 0.001; Fig. 3B).
AnxA5 seemed to have a preventive effect with respect to post-ischemic LV dilation according to nearly 
equal LV volumes as compared to the sham group after three weeks (EDV: 30.4 ± 1.2 μl, P = 1.000; Fig. 3A, and 
ESV: 11.2 ± 1.0 μl, P = 0.188; Fig. 3B), in contrast to vehicle treatment which caused obvious LV dilation (both 
P < 0.001; Fig. 3A,B).
The limited LV dilation was associated with a significantly better LV function, as expressed by preserved EF 
in the AnxA5 group compared to vehicle (52.5 ± 2.4% vs. 40.8 ± 2.9%, P = 0.019; Fig. 3C) while no significant 
difference was observed after two days (54.6 ± 3.5% vs. 44.7 ± 3.0%, P = 0.074; Fig. 3C).
Annexin A5 reduces LV fibrous content and preserves LV wall thickness. Histological evaluation 
of LV fibrous content endorsed the aforementioned results as assessed by cardiac MRI. AnxA5 administration 
caused a reduction of LV fibrous content three weeks after MI-R as compared to the vehicle group (11.4 ± 1.1% vs. 
19.8 ± 1.8%; P = 0.001, Fig. 4A). This was accompanied by an increased wall thickness of the infarcted LV wall in the 
AnxA5 compared to the vehicle group (0.90 ± 0.04 mm vs. 0.75 ± 0.04 mm, P = 0.041; Fig. 4C). Wall thickness of the 
border zone area (1.02 ± 0.02 mm vs. 1.03 ± 0.03 mm, P = 1.000) and interventricular septum (1.00 ± 0.04 mm vs. 
1.10 ± 0.04 mm, P = 0.326) were not affected by AnxA5 therapy as compared to vehicle (Fig. 4C).
Furthermore, LV wall thickness in the infarct area was decreased in the vehicle group compared to the sham 
group (0.93 ± 0.03 mm; P = 0.008), while LV wall thickness in the infarct area was preserved in the AnxA5 
group (P = 1.000) when compared to the sham group (Fig. 4C). Besides, both the AnxA5 (P = 0.047) and vehicle 
(P = 0.001) group showed an increased wall thickness of the interventricular septum compared to the sham group 
(0.85 ± 0.04 mm) indicating compensatory concentric hypertrophy (Fig. 4C).
Annexin A5 causes reduction of the local inflammatory response. Histological analysis two days 
after MI-R showed a significant increase in cardiac macrophages in both the vehicle (P < 0.001) and AnxA5 
(P < 0.05) treated group when compared to sham mice, indicating an increase of the local inflammatory response 
following MI-R injury (Fig. 5A). Interestingly, the number of cardiac macrophages was reduced following AnxA5 
treatment compared to vehicle in the infarct area (134.5 ± 21.3 vs. 306.4 ± 63.1 per mm2, P = 0.007), border zones 
(124.9 ± 14.1 vs. 243.0 ± 18.4 per mm2, P < 0.001) and interventricular septum (59.1 ± 8.4 vs. 101.9 ± 12.4 per 
mm2, P = 0.037). Taken together, this suggests, although increased compared to sham, AnxA5 treatment results 
in a reduction of the post-ischemic inflammatory response.
Three weeks after MI-R injury the number of cardiac macrophages is increased in both the vehicle (P < 0.001) 
and AnxA5 (P < 0.05) group when compared to the sham group, indicating the local inflammatory response is 
still increased following MI-R injury at this time point (Fig. 5G). Intriguingly, the number of cardiac macrophages 
was reduced following AnxA5 treatment compared to vehicle treated mice in the infarct area (240.6 ± 25.1 vs. 
376.2 ± 47.3 per mm2, P = 0.029) and border zones (154.1 ± 9.9 vs. 274.6 ± 43.1 per mm2, P = 0.018), but not in the 
interventricular septum (39.3 ± 5.3 vs. 40.0 ± 8.7 per mm2, P = 1.000). Taken together, this means AnxA5 treat-
ment not only reduces the early inflammatory response, but also the extended chronic inflammatory response.
Figure 2. Contrast-enhanced MR imaging. Two days after MI-R no difference in infarct size was observed 
between the groups (n = 13–15). However, after three weeks the AnxA5 group displayed a reduced infarct size 
as compared to the vehicle group (A). Representative Gd-DPTA-enhanced MR images (B) two days and three 
weeks after MI-R of the vehicle and AnxA5 group, red line indicates epicardial border, green line indicates 
endocardial border and yellow line indicates infarct area. Data are mean ± SEM. #P < 0.05 vs. vehicle.
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AnxA5 treatment reduces the number of proliferating macrophages. To further investigate the 
mechanism behind the observed reduced inflammatory response, serum CCL2 concentrations two and three 
weeks port MI-R injury were measured. No significant differences were observed between all groups regarding 
serum CCL2 concentrations at both time points (Supplementary Fig. S2).
Next, the number of proliferating macrophages (Mac3+/Ki67+ cells) was quantified. Two days post MI-R 
injury the number of proliferating macrophages is significantly reduced in the infarct area and border zones, 
but not in the interventricular septum in AnxA5 treated mice compared to vehicle treated mice (infarct area: 
73.8 ± 17.0 vs. 188.6 ± 41.7, P = 0.009; border zones: 69.3 ± 8.6 vs. 142.2 ± 27.5, P = 0.008 and septum: 21.8 ± 3.7 
vs. 28.5 ± 6.0 per mm2, P = 0.852; Fig. 5B). Compared to sham (infarct area: 13.9 ± 2.3, border zones: 12.9 ± 3.4 
and septum: 11.5 ± 3.0 per mm2), vehicle treated mice show a significant increase in proliferating macrophages in 
the infarct area (P < 0.001) and border zones (P < 0.001) of the LV wall, while AnxA5 treated mice only show an 
increased number of proliferating macrophages in the border zones (P = 0.015).
Three weeks post MI-R injury no differences in proliferating macrophages could be observed between AnxA5 
treated mice and vehicle treated mice (Fig. 5H). In the infarct area and border zones the number of proliferating 
macrophages was significantly increased in both the AnxA5 and vehicle group compared to the sham group 
(infarct area: AnxA5: 31.4 ± 4.9, P = 0.008,and vehicle: 47.9 ± 7.0, P < 0.001 both vs. sham: 3.7 ± 1.1 per mm2; 
border zones: AnxA5: 20.8 ± 2.4, P = 0.015 and vehicle: 30.8 ± 5.2, P < 0.001 both vs. sham: 3.8 ± 0.9 per mm2).
AnxA5 stimulation reduces IL-6 production by macrophages in vitro. Finally, we investigated the 
effect of AnxA5 stimulation on cytokine production of bone-marrow derived macrophages (Fig. 6). AnxA5 stim-
ulation reduces IL-6 production significantly compared to vehicle (1071 ± 28 vs. 1455 ± 65 pg/ml; P < 000.1).
Discussion
This study shows a beneficial therapeutic effect of human recombinant AnxA5 administration following MI-R 
injury. By using hypercholesterolemic conditions and administering treatment directly after reperfusion results 
can be interpreted as clinically relevant. AnxA5 treatment resulted in accumulation of AnxA5 in the infarct 
area subsequently leading to a reduced infarct size, most likely mediated by attenuation of the inflammatory 
response. These results translated into limited LV dilation and improved cardiac function three weeks after MI-R. 
To our knowledge this is the first time that such a huge therapeutic effect (a 28.6% increase in EF) is shown after 
a follow-up of three weeks and treatment was started post-reperfusion. Although other groups have reported 
strong beneficial effects on EF of several compounds22–24, these studies started the therapeutic intervention before 
Figure 3. Cardiac MR imaging of LV volumes and function. Assessment of LV volumes and function two days 
and three weeks after MI-R (n = 12–15). AnxA5 therapy prevented the increase in end-diastolic volume (EDV) 
(A) and end-systolic volume (ESV) (B) accompanied by a preserved ejection fraction (EF) (C) as compared 
to vehicle three weeks post MI-R. Representative transversal short-axis MR images at end-diastole (ED) and 
end-systole (ES) two days (D) and three weeks (E) following MI-R in the sham, AnxA5 and vehicle groups, red 
line indicates epicardial border and green line indicates endocardial border. Data are mean ± SEM. #P < 0.05, 
##P < 0.01, ###P < 0.001 all vs. vehicle, *P < 0.05 and ***P < 0.001 both vs. sham.
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reperfusion, a setting that does not really mimics the situation seen in clinical treatment of patients. We found a 
striking increase in EF by 28.6% following post-reperfusion AnxA5 treatment.
Since infarct healing can be seen as a biphasic process with an inflammatory phase followed by a reparative 
and proliferative phase25, therapeutic effects are ideally analyzed after completion of both phases. Therefore we 
analyzed the effects of AnxA5 at two days and three weeks after MI-R. The fact that especially after three weeks 
AnxA5 treatment resulted in improved cardiac function and reduced infarct sizes, is very promising for the even-
tual translation of AnxA5 treatment to a clinical setting in which long term effects are desired.
Hypercholesterolemia is a primary risk factor for MI in human26 and it affects IS following MI-R injury in 
mice27–29 making the condition of value to implement in translational animal models. ApoE*3-Leiden mice 
develop hypercholesterolemia with subsequent atherosclerosis when fed a high-cholesterol diet, but not following 
a chow diet30. In our study we found a cardioprotective effect of AnxA5 treatment following MI-R in hypercholes-
terolemic ApoE*3-Leiden mice, although AnxA5 had no effects on plasma cholesterol levels. These mice mimic 
the clinical situation of most MI patients regarding hypercholesterolemia, and thereby adding more value to the 
found cardioprotective effect of AnxA5.
We demonstrated a reduced infarct size following MI-R injury as a result of AnxA5 treatment which was 
accompanied by preserved LV wall thickness of the infarcted area after three weeks. This might explain the 
improved cardiac function, since attenuation of post-ischemic LV remodeling is a prerequisite to improve LV 
function and finally attain prolonged survival31. In line with our results Hale et al. reported that therapeutic 
administration of Diannexin caused significantly smaller areas of no-reflow and obviously reduced infarct size 
within hours following severe myocardial ischemia in rabbits21. Diannexin, a 73 kDa recombinant dimer of the 
endogenous human Annexin A5 protein, has also been reported to have anti-thrombotic activities. Diannexin 
and annexin A5 bind PS with K(D) values of 0.6 and 5 nm, respectively, and both bind to the same subpopulation 
of PS-exposing platelets, thus inhibiting both the adverse effects of PS. Annexin A5 (35.7 kDa) is rapidly cleared 
from the circulation. In contrast to Annexin A5 which is rapidly cleared from the circulation, Diannexin, has 
an extended half-life, probably due to the higher molecular weight and the decreased renal clearance rate21,32,33. 
However, in this study we focus on the effects on natural occurring Annexin A5.
Molecular MR imaging with an annexin-labeled magnetofluorescent nanoparticle in combination with 
delayed-enhancement MRI has been shown to distinguish cardiomyocyte apoptosis from necrosis in vivo within 
4 to 6 hours following MI-R injury34. Large areas of apoptotic but viable myocardium were revealed emphasizing 
its susceptibility to pharmacological intervention and salvation of apoptotic myocardium34. During the early 
Figure 4. LV fibrous content and LV wall thickness. Histological analysis after three weeks (n = 9–10) showed 
a significant reduced LV fibrous content in the AnxA5 group compared to the vehicle group (A). Representative 
images (B) of Sirius red staining of cross-sections of the whole heart in the vehicle group and the AnxA5 group. 
Scale bar: 500 μm. LV wall thickness was significantly increased in the infarct area after AnxA5 treatment (C). 
Data are mean ± SEM. #P < 0.05 vs. vehicle, *P < 0.05, **P < 0.01, ***P < 0.001 all vs. sham.
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phase of apoptosis in cardiomyocytes, endogenous AnxA5 is translocated and externalized35,36. Reversibility of 
this apoptotic process was demonstrated, as exogenous AnxA5 binds to externalized PS, thereby shielding of 
the “eat me” signal18. We suggest that treatment with AnxA5, like we performed in the current study, affects the 
exposed PS and thus attenuate the pro-apoptotic, but also the pro-inflammatory status of the myocardium. Up to 
at least 6 hours after a solitary MI-R insult AnxA5 binding to externalized PS resulted in restored sarcolemmal PS 
asymmetry after AnxA5 internalization18, which might be one of the mechanisms behind the observed decrease 
in IS after AnxA5 treatment.
Following AnxA5 treatment, the number of cardiac macrophages was dramatically decreased both two days 
and three weeks post MI-R compared to vehicle treatment. Macrophages play a dual role following MI-R injury, 
in the early phase after an infarction they help to clear the infarct area from cell debris and matrix components, 
Figure 5. Local inflammatory response and macrophage proliferation. Quantification of the number of 
infiltrated macrophages showed an decreased number of infiltrated macrophages in the border zones and 
infarct area two days (n = 3–5) following MI-R in the AnxA5 group (A). Mac3/Ki67 double staining revealed 
a significant reduction in the number of proliferating macrophages in the border zones and infarct area after 
two days in the AnxA5 treated mice as compared to vehicle (n = 5–6; B). Three weeks after MI-R the number 
of infiltrated macrophages is significantly reduced in the border zones and infarct area upon AnxA5 treatment 
(G). No differences were observed regarding the number of proliferating macrophages three weeks after MI-R 
between AnxA5 and vehicle groups (H). Representative images of Mac3 staining (C,D,I and J) and Mac3/Ki67 
double staining (E,F,K and L) of the infarct area. Nuclei are shown in blue, Mac3 staining in green and Ki67 in 
red, arrowheads indicate positive cells. Scale bar: 50 μm. Data are mean ± SEM. #P,0.05, ##P < 0.01, ###P < 0.001 
all vs. vehicle, *P < 0.05, **P < 0.01 and ***P < 0.001 all vs. sham.
www.nature.com/scientificreports/
7SCientifiC RepoRts |  (2018) 8:6753  | DOI:10.1038/s41598-018-25143-y
which can act like damage associated molecular patterns, before they trigger the innate immune response37 as 
shown by Fig. 5 where an increase of cardiac macrophages can be found after MI-R in both AnxA5 and vehicle 
groups in comparison to the sham group. On the other hand, macrophages themselves can produce cytokines, 
which increase the inflammatory response1,38. This is one of the reasons for the disappointing results of present 
anti-inflammatory therapies in clinical trials, despite promising pre-clinical studies39. Therefore it seems plausible 
that rather than total abolishment of the inflammatory response, suppression of inflammation is beneficial follow-
ing MI-R injury. This explains the observed striking beneficial results regarding IS and cardiac function following 
AnxA5 treatment, while the number of cardiac macrophages is increased compared to sham mice.
The cardiac macrophage population is maintained by both monocyte infiltration and local proliferation of 
macrophages. We found no differences in serum CCL2 concentrations, a critical player in monocyte recruit-
ment to sites with tissue injury, following AnxA5 treatment. Therefore, we focused on the role of AnxA5 treat-
ment on macrophage proliferation following MI-R injury. Interestingly, number of proliferating macrophages 
was significantly reduced two days post MI-R injury following AnxA5 treatment. However, the percent-
age proliferating macrophages was comparable in both the vehicle and AnxA5 group. Immediately follow-
ing MI-R injury the resident macrophage population in the infarct area undergoes apoptosis and is replaced 
by mainly Ly6Chigh monocytes, which differentiate into pro-inflammatory macrophages40. This population of 
pro-inflammatory macrophages is maintained by both recruitment of Ly6Chigh monocytes as well as prolifera-
tion of the pro-inflammatory macrophages41. Since we did not observe differences in CCL2 concentrations and 
percentage proliferating macrophages was unaffected, the mechanism by which AnxA5 treatment reduces the 
number of cardiac macrophages is subject of future research.
We observed a decrease in IL-6 production by bone-marrow derived macrophages following AnxA5 stimu-
lation. Recently, it has been shown that IL-6-deficient mice show reduced acute MI-R injury42. Furthermore, a 
correlation between IL-6 concentrations and myocardial damage was found in patients suffering from ischemic 
events43. This is in line with our results regarding IL-6 production by macrophages and the cardioprotective effect 
of AnxA5 in vivo. However, the exact mechanism by which AnxA5 regulates IL-6 production in this setting is 
subject for future research.
Radiolabeled AnxA5 is rapidly cleared from blood and accumulates in apoptotic tissue20. Previously, we have 
shown AnxA5 treatment leads to accumulation of AnxA5 at sites of injured vessel wall after systemic treatment, 
while AnxA5 is rapidly cleared from the blood19. In the current study, we show accumulation of AnxA5 in the 
infarct area following systemic AnxA5 treatment. The short half-life in blood, accumulation in the infarct area 
and cardioprotective effect suggests that AnxA5 is a safe and promising therapeutic agent.
Taken together, we showed a potential therapeutic role for human recombinant AnxA5 against MI-R injury in 
a clinical relevant setting. By suppression of the inflammatory response, AnxA5 attenuates long term adverse LV 
remodeling and improve cardiac function. A recent study by Ziegler et al., directed at the inhibition of inflamma-
tion using CD39 showed similar inhibitory effects on adverse post MI-R remodeling44. This underscores the new 
therapeutic potential of inhibiting inflammation in post MI-R remodeling.
Methods
Animals and diets. This study was performed in compliance with Dutch government guidelines and the 
Directive 2010/63/EU of the European Parliament. All animal experiments were approved by the Institutional 
Committee for Animal Welfare of the Leiden University Medical Center (LUMC). Transgenic female ApoE*3-
Leiden mice45, backcrossed for more than 40 generations on a C57Bl/6 J background (bred in the animal facility of 
the LUMC), aged 8–10 weeks at the start of a dietary run-in period were used for this experiment. Mice were fed 
a semisynthetic Western-type diet supplemented with 0.4% cholesterol (AB Diets, Woerden, The Netherlands) 
4 weeks prior to surgery, which was continued throughout the complete experiment. Mice were housed under 
standard conditions in conventional cages and received food and water ad libitum.
Plasma lipid analysis. Plasma levels of total cholesterol (TC) and triglycerides (TG) were determined for 
randomization one week before surgery and at the end of the experiment. After a 4 hours fasting period, plasma 
Figure 6. In vitro effect of AnxA5 stimulation on bone-marrow derived macrophages. IL-6 production 
was significantly reduced following AnxA5 stimulation (n = 5) compared to vehicle. Data are mean ± SEM. 
###P < 0.001 vs. vehicle.
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was obtained via tail vein bleeding (~50 μL) and assayed for total cholesterol (TC) and triglycerides (TG) levels 
using commercially available enzymatic kits according to the manufacturer’s protocols (11489232 and 11488872, 
respectively; Roche Diagnostics, Mannheim, Germany).
Surgical myocardial ischemia-reperfusion model and Annexin A5 administration. MI was 
induced by MI-R at day 0 in 12–14 weeks old female ApoE*3-Leiden mice as described previously46. Briefly, 
mice were pre-anesthetized with 5% isoflurane in a gas mixture of oxygen and room air and placed in a supine 
position on a heating pad (37 °C). After endotracheal intubation and ventilation (rate 160 breaths/min, stroke 
volume 190 μL; Harvard Apparatus, Holliston, MA, USA), mice were kept anesthetized with 1.5–2% isoflurane. 
Subsequently, a left thoracotomy was performed in the 4th intercostal space and the left anterior descending 
(LAD) coronary artery was ligated during 45 minutes using a 7–0 prolene suture knotted on a 2 mm section of 
a plastic tube followed by permanent reperfusion. Ischemia was confirmed by myocardial blanching. During 
this period muscle flaps were folded back and covered with a pre-warmed wet surgical mesh. Body temperature 
was kept constant between 35–37 °C. After 35 minutes of ischemia mice received an intraperitoneal injection of 
lidocain (6 mg/kg) to prevent cardiac arrhythmias caused by reperfusion. After 45 minutes of ischemia, perma-
nent reperfusion was established. Subsequently, the thorax was closed in layers with 5–0 prolene suture and mice 
were allowed to recover. Analgesia was obtained with buprenorfine s.c. (0.1 mg/kg) pre-operative and 10–12 h 
post-operative. After surgery, animals were randomly grouped to receive daily administration of intraperitoneal 
injections with 1 mg/kg human recombinant annexin A5 (AnxA5; Athera Biotechnologies) in a volume of 200 μl, 
or NaCl 0.9% w/v (vehicle) as a control. Sham operated animals were operated similarly but without ligation of 
the LAD, and received intraperitoneal injections with NaCl 0.9% w/v. Injections were administered direct after 
surgery and between 12:00 p.m. and 2:00 p.m. the days thereafter. After two days or three weeks, mice were euth-
anized by bleeding and explantation of heart under general anesthesia with 1.5–2% isoflurane in a gas mixture of 
oxygen and room air. Hearts were quickly excised, immersion-fixated in 4% paraformaldehyde for 24 hours and 
embedded in paraffin. The heart and body weight were measured from all animals.
Cardiac magnetic resonance imaging. Cardiac parameters were assessed two days and three weeks post 
MI-R using a 7-Tesla MRI (Bruker Biospin, Ettlingen, Germany) equipped with a combined gradient and shim 
coil, which is inserted into the magnet bore. Mice were pre-anesthetized as described above and kept anesthetized 
with 1.5–2% isoflurane. Respiratory rate was monitored by a respiration detection cushion, which was placed 
underneath the thorax and connected to a gating module to monitor respiratory rate (SA Instruments, Inc., Stony 
Brook, NY). Image reconstruction was performed using Bruker ParaVision 5.1 software.
Infarct size. To determine infarct size, contrast enhanced MR imaging was performed after injection of a 
150 µL bolus (0.5 mmol/ml) of gadolinium-DPTA (Gd-DPTA, Dotarem, Guerbet, the Netherlands) via the tail 
vein. A gradient echo sequence (FLASH) was used to acquire a set of 14 contiguous 0.7 mm contrast-enhanced 
slices in short-axis orientation covering the entire heart. Imaging parameters were: echo time of 1.9 ms, repetition 
time of 84.16 ms, field of view (33 mm2), and a matrix size of 192 × 256.
Left ventricular function. Assessment of cardiac function was performed with a high-resolution 2D 
FLASH cine sequence to acquire a set of 9 contiguous 1 mm slices in short-axis orientation covering the entire 
heart. Imaging parameters were: echo time of 1.49 ms, repetition time of 5.16 ms, field of view (26 mm2), and a 
matrix size of 144 × 192.
Image analysis. All MR image data was analyzed with the MASS for mice software package (MEDIS, Leiden, 
the Netherlands). The endocardial and epicardial borders were manually delineated and a reference point was 
positioned by an investigator blinded to treatment. Subsequently, the infarcted area of the LV, end-diastolic vol-
ume (EDV), end-systolic volume (ESV), ejection fraction (EF) were computed automatically.
LV fibrous content and LV wall thickness. Paraffin-embedded hearts were cut into serial transverse 
sections of 5 μm along the entire long-axis of the LV and mounted on slides. To analyze collagen deposition as an 
indicator of the fibrotic area, every 50th section of each heart was stained with Sirius Red. LV fibrous content, as 
a representation of IS, was determined by planimetric measurement of all sections and calculated as fibrotic area 
divided by the total LV wall surface area including the interventricular septum.
LV wall thickness was measured in five different sections centralized in the infarct area. Per section, wall 
thickness was analyzed at 3 places equally distributed in the infarcted area, both border zones, and 2 places of the 
interventricular septum. Measurements were performed perpendicular to the ventricular wall. Corresponding 
areas were used for measurements in the non-infarcted sham group. All measurements were performed by an 
observer blinded to the groups, using the ImageJ 1.47 v software program (NIH, USA).
Immunohistochemistry. To evaluate AnxA5 accumulation in the infarct area paraffin section of the 
mid-infarct region of the heart were stained using antibodies against AnxA5 (anti-human annexin V, 3357–100, 
Biovision, Milpitas, CA, USA), while counterstaining was performed using haematoxylin.
For analysis of the cardiac inflammatory response paraffin sections of the mid-infarct region of the heart 
were stained using antibodies against macrophages (anti-Mac3, 550292; BD Pharmingen, San Diego, CA, USA) 
and to quantify the number of proliferating macrophages antibodies against proliferation marker Ki67 were used 
(anti-Ki67, ab16667; Abcam, Cambridge, UK). The number of macrophages and proliferating macrophages was 
expressed as a number per mm2 in the septum (2 areas), border zones (2 areas), and infarcted myocardium (3 areas).
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Bone-marrow derived macrophages. Bone-marrow derived cells were isolated from ApoE*3-Leiden 
mice and subjected to murine macrophage colony-stimulating factor (M-CSF) (20 ng/μl; Miltenyi Biotec) to 
stimulate differentiation into macrophages.
Macrophages were stimulated by exposure to 8% heat-inactivated FCS in the presence and absence of AnxA5 
(2 µM). The cells were incubated overnight at 37 °C in 5% CO2 atmosphere. Next, bone marrow derived mac-
rophage were stimulated with or without LPS (10 ng/ml) for six hours and the supernatants were collected. 
Subsequently, IL-6 production by these bone marrow-derived macrophages was analyzed by ELISA.
ELISA. To study the effects of AnxA5 on systemic inflammation, an ELISA kit (Cat. No. 555260, BD 
Biosciences, San Diego, CA, USA) for cytokine concentration of chemokine (C-C motif) ligand 2 (CCL2) was 
used. Furthermore, the IL-6 production by bone-marrow derived macrophages in vitro was measured using 
an ELISA kit (Cat. No. 555240 (IL-6), BD Biosciences, San Diego, CA, USA), according to the manufacturer’s 
instructions.
Statistical analysis. Values were expressed as mean ± SEM. Comparisons of parameters between the sham, 
AnxA5, and vehicle groups were made using 1-way analysis of variance (ANOVA) with Bonferroni’s correction or 
2-way ANOVA with repeated measures and Bonferroni’s post-test in case of multiple time points. Comparisons 
between AnxA5 and vehicle were made using (un)paired t-tests. A value of P < 0.05 was considered to represent 
a significant difference. Statistical procedures were performed using IBM SPSS 23.0.0 (SPSS Inc – IBM, Armonk, 
NY, USA) and GraphPad Prism 6.02 (GraphPad Software Inc, La Jolla, CA, USA).
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